AEON

AEON Biopharma Inc

Apr 02 • 04:00PM ET

0.8888

-0.0896 -9.16 %

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ PFE REGN LLY MRK ABT NVS BMY GILD BIIB

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	56.74%	Shs Outstand	12.11M	Perf Week	-11.12%
Market Cap	22.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.95M	Perf Month	-18.46%
Enterprise Value	55.22M	PEG	-	EPS next Q	-0.44	Inst Own	9.66%	Short Float	2.54%	Perf Quarter	-19.20%
Income	-39.22M	P/S	-	EPS this Y	50.38%	Inst Trans	10.57%	Short Ratio	1.87	Perf Half Y	11.10%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-901.45%	Short Interest	0.28M	Perf YTD	-19.20%
Book/sh	-4.55	P/C	7.47	EPS next 5Y	-	ROE	-	52W High	1.45 -38.70%	Perf Year	64.32%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	47.46% -253.12%	ROIC	-	52W Low	0.38 137.01%	Perf 3Y	-99.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	19.82% 11.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-102.58%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.49	EPS Q/Q	-181.83%	SMA20	-17.56%	Beta	0.73	Target Price	8.40
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-19.32%	Rel Volume	0.50	Prev Close	0.98
Employees	8	LT Debt/Eq	-	Earnings	Mar 30 AMC	SMA200	-4.37%	Avg Volume	148.38K	Price	0.89
IPO	Apr 12, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-2456.10% -	Trades		Volume	74,795	Change	-9.16%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-23	Initiated	H.C. Wainwright	Buy	$18

Apr-03-26 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards (GlobeNewswire)
Mar-30-26 04:05PM	AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program (GlobeNewswire) -14.70%
Mar-25-26 08:00AM	AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program (GlobeNewswire)
Mar-09-26 04:05PM	AEON Biopharma Appoints John Bencich as Chief Financial Officer (GlobeNewswire) +7.48%
04:05PM	Loading…
Mar-05-26 04:05PM	AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -5.50%
Jan-21-26 04:05PM	AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions (GlobeNewswire) +13.33% -13.97%
Dec-19-25 06:00PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +6.93%
Dec-15-25 04:05PM	AEON Biopharma Announces Execution of Exchange Agreement with Daewoong (GlobeNewswire) +5.10% +19.21%
Nov-20-25 08:30AM	AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling (GlobeNewswire) -12.79%
Nov-14-25 08:30AM	AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth (GlobeNewswire)
Aug-12-25 04:05PM	AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.08%
May-23-25 04:05PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +13.67%
May-19-25 04:05PM	AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 (GlobeNewswire)
May-14-25 04:05PM	AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Apr-25-25 04:05PM	AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -6.43%
Apr-21-25 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer (GlobeNewswire)
Mar-27-25 04:05PM	AEON Biopharma Announces CEO Transition (GlobeNewswire) -8.56% -7.34%
Mar-24-25 04:05PM	AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +8.03% -7.28%
Mar-04-25 08:00AM	AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -21.31%
Feb-24-25 02:00PM	AEON Biopharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -43.89%
Feb-07-25 04:05PM	AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -6.93%
Jan-07-25 09:37AM	AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering (GlobeNewswire) +5.24%
Jan-06-25 09:00AM	AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering (GlobeNewswire) -63.09%
Jan-03-25 08:02PM	AEON Biopharma, Inc. Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-13-24 04:05PM	AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.11% -11.35%
Sep-30-24 08:00AM	AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting (GlobeNewswire) +13.18%
Aug-21-24 09:55AM	AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-19-24 04:05PM	AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire)
04:05PM	Loading…
Aug-12-24 04:05PM	AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-24 08:00AM	AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 (GlobeNewswire) +7.84%
May-29-24 09:35AM	Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround (Zacks) +8.70%
08:00AM	AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan (GlobeNewswire)
May-14-24 04:05PM	AEON Biopharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 09:35AM	AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.21%
08:00AM	AEON Biopharma Provides Update on Development Pipeline (GlobeNewswire)
May-03-24 04:08PM	US Equity Markets Close Higher Friday Following Weak Jobs Report (MT Newswires) -49.40%
03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
02:37PM	Top Midday Decliners (MT Newswires)
09:05AM	Sector Update: Health Care Stocks Mixed Pre-Bell Friday (MT Newswires)
08:31AM	AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial (MT Newswires)
07:00AM	AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine (GlobeNewswire)
Mar-30-24 10:53PM	CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
Mar-29-24 04:15PM	AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
03:45PM	AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 04:30PM	AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine (GlobeNewswire) -11.60% -12.57%
04:29PM	AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements (GlobeNewswire)
Jan-18-24 04:05PM	AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference (GlobeNewswire) +10.35%
Dec-12-23 08:00AM	AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine (GlobeNewswire)
Nov-15-23 04:49AM	AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements (GuruFocus.com) +7.61%
Nov-13-23 08:15AM	AEON Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 04:05PM	AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine (GlobeNewswire)
Aug-29-23 08:00AM	AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® (GlobeNewswire)
Aug-24-23 08:00AM	AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache (GlobeNewswire) +14.91%
Aug-16-23 07:00AM	Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma (GlobeNewswire) +7.06%
Jul-24-23 07:00AM	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update (GlobeNewswire) -15.13%

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FISCHER JOST	Director	May 21 '25	Buy	0.49	60,000	29,250	266,785	May 23 04:46 PM
FISCHER JOST	Director	May 20 '25	Buy	0.51	60,000	30,360	206,785	May 21 04:50 PM
FISCHER JOST	Director	May 19 '25	Buy	0.50	50,000	24,940	146,785	May 21 04:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AEON

AEON Biopharma Inc

Upgrade your Finviz experience